Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV)
CUSIP: 004890109
Q3 2023 13F Holders as of 30 Sep 2023
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 38,870,454
- Total 13F shares
- 15,093,861
- Share change
- -32,670
- Total reported value
- $144,297,342
- Price per share
- $9.56
- Number of holders
- 43
- Value change
- -$326,020
- Number of buys
- 19
- Number of sells
- 13
Quarterly Holders Quick Answers
What is CUSIP 004890109?
CUSIP 004890109 identifies ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 004890109:
Top shareholders of ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
12%
|
4,810,508
|
$62,344,184 | — | 30 Jun 2023 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
7.7%
|
3,007,858
|
$38,981,840 | — | 30 Jun 2023 | |
| Sands Capital Alternatives, LLC |
13F
|
Company |
4.3%
|
1,652,605
|
$21,417,761 | — | 30 Jun 2023 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
4.2%
|
1,649,646
|
$21,379,412 | — | 30 Jun 2023 | |
| Chione Ltd |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,848,632
|
$16,741,549 | — | 26 Jun 2023 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.3%
|
888,130
|
$11,510,165 | — | 30 Jun 2023 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.5%
|
597,469
|
$7,743,198 | — | 30 Jun 2023 | |
| BlackRock Finance, Inc. |
13F
|
Company |
1.4%
|
533,355
|
$6,912,281 | — | 30 Jun 2023 | |
| NEA Management Company, LLC |
13F
|
Company |
1.2%
|
481,677
|
$6,242,534 | — | 30 Jun 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
1%
|
403,275
|
$5,226,444 | — | 30 Jun 2023 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.78%
|
304,411
|
$3,945,167 | — | 30 Jun 2023 | |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
888,130
|
$3,863,366 | — | 17 Nov 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.46%
|
178,453
|
$2,312,750 | — | 30 Jun 2023 | |
| STATE STREET CORP |
13F
|
Company |
0.32%
|
125,976
|
$1,632,649 | — | 30 Jun 2023 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.26%
|
100,000
|
$1,296,000 | — | 30 Jun 2023 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.2%
|
76,852
|
$996,002 | — | 30 Jun 2023 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.18%
|
68,678
|
$890,067 | — | 30 Jun 2023 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.16%
|
60,958
|
$790,016 | — | 30 Jun 2023 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.12%
|
46,910
|
$607,954 | — | 30 Jun 2023 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.06%
|
24,795
|
$321,343 | — | 30 Jun 2023 | |
| BARCLAYS PLC |
13F
|
Company |
0.04%
|
14,263
|
$184,849 | — | 30 Jun 2023 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.03%
|
11,821
|
$153,200 | — | 30 Jun 2023 | |
| EXCHANGE TRADED CONCEPTS, LLC |
13F
|
Company |
0.03%
|
11,709
|
$151,749 | — | 30 Jun 2023 | |
| AAF Wealth Management, LLC |
13F
|
Company |
0.03%
|
10,678
|
$138,387 | — | 30 Jun 2023 | |
| UBS Group AG |
13F
|
Company |
0.03%
|
9,780
|
$126,749 | — | 30 Jun 2023 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.02%
|
8,986
|
$116,458 | — | 30 Jun 2023 | |
| MORGAN STANLEY |
13F
|
Company |
0.02%
|
8,505
|
$110,225 | — | 30 Jun 2023 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.02%
|
7,624
|
$98,807 | — | 30 Jun 2023 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.02%
|
6,927
|
$89,774 | — | 30 Jun 2023 | |
| AMERICAN INTERNATIONAL GROUP, INC. |
13F
|
Company |
0.01%
|
4,183
|
$54,212 | — | 30 Jun 2023 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.01%
|
4,062
|
$52,644 | — | 30 Jun 2023 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.01%
|
3,305
|
$42,833 | — | 30 Jun 2023 | |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM |
13F
|
Company |
0.01%
|
2,891
|
$37,467 | — | 30 Jun 2023 | |
| CITIGROUP INC |
13F
|
Company |
0.01%
|
2,790
|
$36,158 | — | 30 Jun 2023 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
0.01%
|
2,275
|
$29,484 | — | 30 Jun 2023 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
907
|
$12,000 | — | 30 Jun 2023 | |
| Legal & General Group Plc |
13F
|
Company |
0%
|
839
|
$10,873 | — | 30 Jun 2023 | |
| STRS OHIO |
13F
|
Company |
0%
|
800
|
$10,000 | — | 30 Jun 2023 | |
| AMALGAMATED BANK |
13F
|
Company |
0%
|
781
|
$10,000 | — | 30 Jun 2023 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
732
|
$9,487 | — | 30 Jun 2023 | |
| Ameritas Investment Partners, Inc. |
13F
|
Company |
0%
|
695
|
$9,007 | — | 30 Jun 2023 | |
| FMR LLC |
13F
|
Company |
0%
|
422
|
$5,469 | — | 30 Jun 2023 |
Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) as of Q3 2023
As of 30 Sep 2023,
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) was held by
43 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,093,861 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS LLC, Sands Capital Ventures, LLC, CITADEL ADVISORS LLC, WELLINGTON MANAGEMENT GROUP LLP, MARSHALL WACE, LLP, BlackRock Inc., VANGUARD GROUP INC, NEA Management Company, LLC, and FEDERATED HERMES, INC..
This page lists
43
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2023 vs Q2 2023 Across Filers
Q2 2023 holders
40
Q3 2023 holders
43
Holder diff
3
| Investor | Q2 2023 Shares | Q3 2023 Shares | Share Diff | Share Chg % | Q2 2023 Value $ | Q3 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.